Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party
Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party
复制标题
DOI：
10.1002/cncr.31755
复制
发表时间：
2019-01-01
期刊：
影响因子：
6.2
通讯作者：
Sureda, Anna
中科院分区：
文献类型：
--
作者：
Bazarbachi, Ali;Boumendil, Ariane;Sureda, Anna
背景同种异基因干细胞移植(allo-SCT)后发生疾病进展的霍奇金淋巴瘤(HL)患者的治疗仍然具有挑战性。方法作者评估了2010年至2014年间在欧洲血液和骨髓移植参与中心进行匹配的相关或非相关异基因干细胞移植后出现疾病复发或进展的184名成年HL患者的预后。结果接受布洛昔单抗(BV)抢救治疗的80例患者与未接受BV抢救治疗的104例患者进行比较。BV组的患者更年轻(中位年龄30岁比34岁)，更有可能在移植前接受BV(65%比46%)或移植后接受供者淋巴细胞输注(66%比33%)。两组在其他方面具有可比性。BV组患者移植后接受BV的中位数为6剂，完全缓解率为29%，部分应答率为45%，稳定期为26%。异基因干细胞移植后对BV的应答似乎不受移植前接受BV的影响。尽管BV组存活患者的中位随访期较长(33个月对23个月；P
Background The treatment of patients with Hodgkin lymphoma (HL) who develop disease progression after undergoing allogeneic stem cell transplantation (allo-SCT) remains challenging. Methods The authors assessed outcomes in 184 adult patients with HL who developed disease recurrence or progression after a matched related or unrelated allo-SCT at European Society for Blood and Marrow Transplantation-participating centers between 2010 and 2014. Results Eighty patients who received brentuximab vedotin (BV) salvage therapy were compared with 104 patients who did not. Patients in the BV group were younger (median age of 30 years vs 34 years) and were more likely to receive pretransplant BV (65% vs 46%) or posttransplant donor lymphocyte infusion (66% vs 33%). The 2 groups otherwise were comparable. Patients in the BV group received a median of 6 doses of posttransplant BV, resulting in a complete remission rate of 29%, a partial response rate of 45%, and a stable disease rate of 26%. Response to BV after allo-SCT did not appear to be affected by receipt of pretransplant BV. Despite a longer median follow-up for surviving patients in the BV group (33 months vs 23 months; P